Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
14
×
Tags
biotech
14
×
life sciences
national blog main
14
×
boston blog main
boston top stories
clinical trials
national top stories
san francisco blog main
deals
fda
san diego blog main
san diego top stories
startups
raleigh-durham blog main
san francisco top stories
new york blog main
raleigh-durham top stories
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
medical device
national
new york top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
glaxosmithkline
investing
san diego
sanofi
alexion pharmaceuticals
autoimmune disorders
What
disease
14
×
drug
medicines
new
companies
roundup
therapeutics
adds
bio
cancer
control
deal
established
fda
fight
gene
hepatitis
infectious
known
liver
lung
nash
news
pharma
pharmaceuticals
potential
proteins
race
research
therapy
year
according
add
address
advanced
ago
akcea
alliance
allosteric
alnylam’s
Language
unset
Current search:
biotech
×
disease
×
photo
×
" national blog main "
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
4 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed